/ /

CLINICAL

Novartis announces new Cosentyx data in psoriasis treatment, including long-term studyResearchers presented new data on the use of the fully human IL-17A inhibitor Cosentyx (secukinumab, Novartis) in moderate-to-severe psoriasis, at the 25th European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria, September 28 through October 2, 2016.
Crowdsourcing pinpoints unmet needs in eczema researchA new study using crowdsourcing harnesses the power of social media chatter to better understand unmet needs in eczema research.
Which OTC products are good for the acne patient?An expert goes over the pros and cons of some of the available OTC acne products.
Are there certain cosmetics that patients with acne should avoid?An expert discusses which types of products tend to be more comdedogenic and acnegenic.
Is there a certain type of facial foundation that will not cause breakouts?An expert discusses available types of facial foundations and their effect on the skin in regards to acne.
5 facts to know about skin disease and self-esteemPhysical appearance can have a significant impact on the psychosocial health of children and adolescents, especially with identity and self-esteem.
Drug pipeline developments: Alopecia areata and atopic dermatitisPromising treatments are coming for alopecia areata and atopic dermatitis, but they will come at a high cost.
Health execs must brace for autoimmune drug changesA comprehensive understanding of this rapidly increasing drug class is essential to integrate pharmacy and medical claim information.
Five specialty pharmaceutical trends to watchApprovals of specialty pharmaceuticals have far outpaced traditional drugs, and that trend will continue. But that’s not the only specialty medication trend that healthcare executives should have on their radar.
Psoriasis research: IL-17, comorbidities take center stageBased on available evidence, dermatologists should at least discuss biologic drugs with patients who have moderate-to-severe psoriasis and cardiovascular comorbidities. Clearing the skin may improve cardiovascular disease, says an expert.

Poll

View Results